| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 6-phosphogluconate dehydrogenase, decarboxylating, PGD, PGDH |
| Entrez GeneID | 5226 |
| WB Predicted band size | 53.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This PGD antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 236-265 amino acids from the Central region of human PGD. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于PGD(磷酸葡萄糖脱氢酶)抗体的代表性文献摘要(内容基于假设性研究，仅供参考)：
---
1. **文献名称**：*"Phosphogluconate Dehydrogenase (PGD) as a Novel Biomarker in Glioblastoma Multiforme"*
**作者**：Tomiyasu H, et al.
**摘要**：本研究通过免疫组化分析发现，PGD在胶质母细胞瘤组织中高表达，且与患者预后不良相关。实验表明，PGD抗体可特异性标记肿瘤细胞，并提示PGD可能通过调节NADPH水平促进肿瘤代谢重编程。
2. **文献名称**：*"Structural Insights into Human PGD and Its Inhibition by Small Molecules"*
**作者**：Smith JL, Lee K.
**摘要**：利用X射线晶体学解析人源PGD的三维结构，结合单克隆抗体的表位定位，揭示了PGD催化活性位点的关键区域。该研究为开发靶向PGD的抗体药物提供了结构基础。
3. **文献名称**：*"PGD-Specific Antibodies Enhance Chemotherapy Sensitivity in Colorectal Cancer Models"*
**作者**：Chen R, et al.
**摘要**：通过体外和体内实验证明，靶向PGD的抗体可通过抑制NADPH生成，增加结直肠癌细胞对5-FU化疗的敏感性，提示PGD抗体在联合治疗中的潜在价值。
4. **文献名称**：*"Autoantibodies Against PGD in Autoimmune Diseases: Clinical Implications"*
**作者**：Zhang Y, et al.
**摘要**：首次报道系统性红斑狼疮(SLE)患者血清中存在抗PGD自身抗体，其滴度与疾病活动度相关，提示PGD可能参与自身免疫反应的分子机制。
---
**注**：以上文献为示例性质，具体研究请参考真实数据库(如PubMed)中的最新论文。
PGD (phosphogluconate dehydrogenase) is a key enzyme in the pentose phosphate pathway (PPP), primarily catalyzing the oxidative decarboxylation of 6-phosphogluconate to ribulose-5-phosphate, while generating NADPH. This reaction links carbohydrate metabolism to redox balance, nucleotide synthesis, and lipid production. PGD exists in two isoforms: H6PD (hexose-6-phosphate dehydrogenase) in the endoplasmic reticulum and PGD in the cytoplasm. Both isoforms require Mg²⁺/Mn²⁺ as cofactors and function as homodimers.
PGD-derived NADPH is critical for cellular defense against oxidative stress and biosynthesis pathways. Dysregulation of PGD is associated with metabolic disorders, cancer progression, and neurodegenerative diseases. For instance, elevated PGD levels are observed in tumors, where it supports rapid proliferation by providing nucleotides and reducing equivalents. Conversely, PGD deficiency has been linked to rare genetic disorders affecting erythrocyte function.
PGD antibodies are essential tools for studying its expression, localization, and role in diseases. They enable detection via Western blot, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in biomarker discovery and therapeutic targeting. Recent research explores PGD inhibitors as potential anticancer agents, highlighting its clinical relevance. Validated antibodies with high specificity are crucial for distinguishing PGD isoforms and ensuring experimental accuracy in both basic and translational studies.
×
